Viral Vectors & Plasmid DNA Manufacturing Market Report 2021 Key Leaders Analysis, Segmentation, Growth, Future Trends, Gross Margin, Demands, Emerging Technology by Regional Forecast to 2030-With COVID-19 Impact Analysis

To produce viral vectors, the appropriate cells must first be grown and then transfected, typically using a plasmid formulation. The viral vector is then harvested from the cells and formulated for use, either directly as a gene therapy or for the medication of patient cells, such as in CAR-T cell therapies.

The global Viral Vectors & Plasmid DNA Manufacturing market size is expected to be worth around US$ 10.6 billion by 2030, according to a new report by Vision Research Reports.

The global Viral Vectors & Plasmid DNA Manufacturing market size was valued at US$ 3.2 billion in 2020 and is anticipated to grow at a CAGR of 20.8% during forecast period 2021 to 2030.

Get Sample Copy of This Report (Including TOC, List of Tables & Figures, and Chart)@ https://www.visionresearchreports.com/report/sample/38494

Viral Vectors & Plasmid DNA Manufacturing Market (By Type: Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others; By Workflow: Upstream Processing, Downstream Processing; By Application: Antisense & RNAi, Gene, Cell Therapy, Vaccinology; By End-use: Pharmaceutical and Biopharmaceutical Companies; By Disease: Cancer, Genetic Disorders, Infectious Diseases, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030

Report Coverage

Growth Factors

The market is strongly supported by a robust pipeline for gene therapy and vector vaccines and technological advancements in manufacturing vectors. Enhancing in occurrence and frequency rates of cancer and high unmet patient needs with the unusual disorder are anticipated to boost the market growth. The Global Viral Vectors and Plasmid DNA Manufacturing Market report provides a holistic evaluation of the market. The report offers comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Viral vectors are tools intended to transport genetic material into cells. Viruses have progressed to advance particular mechanisms which transport their genomes inside the cells they contaminate. Several types of viral vectors can be used to deliver nucleic acids into the genetic makeup of cells counting retrovirus, adenovirus, lentivirus, adeno-associated virus, and herpes simplex virus. Each virus has its own benefits and drawbacks for specific applications.

Key Players

• Novasep
• Aldevron
• MerckWaismanBiomanufacturing
• Creative Biogene
• The Cell and Gene Therapy Catapult
• Cobra Biologics
• uniQure N.V.
• Addgene
• FUJIFILM Holdings Corporation
• Oxford Biomedicaplc
• Takara Bio Inc.

Market Segmentation

By Vector Type Outlook

• Adenovirus
• Retrovirus
• Plasmid DNA
• AAV
• Lentivirus
• Others

By Workflow Outlook

• Upstream Processing
  • Vector Amplification & Expansion
  • Vector Recovery/Harvesting
• Downstream Processing
  • Purification
  • Fill-finish

By Application Outlook

• Antisense & RNAi
• Gene Therapy
• Cell Therapy
• Vaccinology

By End-use Outlook

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

By Disease Outlook

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

By Regional Outlook

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
• Asia Pacific
  • China
  • Japan
• Latin America
  • Brazil
• Middle East & Africa
  • South Africa

Buy This Premium Research Report, click here@ https://www.visionresearchreports.com/report/cart/38494 or call: +1 9197 992 333

The study objectives of this report are:

• To analyze and study the global market capacity, production, value, consumption, status (2017-2020) and forecast (2021-2030);
• Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
• Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
• To define, describe and forecast the market by type, application and region.
• To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
• To identify significant trends and factors driving or inhibiting the market growth.
• To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
• To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
• To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type

7.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Vector Type, 2021-2030

7.1.1. Adenovirus

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. Plasmid DNA

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Lentivirus

7.1.3.1. Market Revenue and Forecast (2017-2030)

7.1.4. Retrovirus

7.1.4.1. Market Revenue and Forecast (2017-2030)

7.1.5. AAV

7.1.5.1. Market Revenue and Forecast (2017-2030)

7.1.6. Others

7.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type

8.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Application Type, 2021-2030

8.1.1. Gene Therapy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Antisense &RNAi

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Cell Therapy

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Vaccinology

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type

9.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Workflow Type, 2021-2030

9.1.1. Upstream Processing (Vector Recovery/Harvesting, Vector Amplification & Expansion)

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Downstream Processing (Fill-finish, Purification)

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Viral Vectors & Plasmid DNA Manufacturing Market, By End-User Type

10.1. Viral Vectors & Plasmid DNA Manufacturing Market, by End-User Type, 2021-2030

10.1.1. Biopharmaceutical and Pharmaceutical Companies

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Research Institutes

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Disease

11.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Disease, 2021-2030

11.1.1. Genetic Disorders

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Cancer

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Infectious Diseases

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Viral Vectors & Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Vector (2017-2030)

12.1.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.1.4. Market Revenue and Forecast, by End-User (2017-2030)

12.1.5. Market Revenue and Forecast, by Disease (2017-2030)

12.1.6. U.S.

12.1.6.1. Market Revenue and Forecast, by Vector (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.1.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.1.7. Market Revenue and Forecast, by Disease (2017-2030)

12.1.8. Rest of North America

12.1.8.1. Market Revenue and Forecast, by Vector (2017-2030)

12.1.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.8.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.1.8.4. Market Revenue and Forecast, by End-User (2017-2030)

12.1.9. Market Revenue and Forecast, by Disease (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Vector (2017-2030)

12.2.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.2.4. Market Revenue and Forecast, by End-User (2017-2030)

12.2.5. Market Revenue and Forecast, by Disease (2017-2030)

12.2.6. UK

12.2.6.1. Market Revenue and Forecast, by Vector (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.2.7. Market Revenue and Forecast, by End-User (2017-2030)

12.2.8. Market Revenue and Forecast, by Disease (2017-2030)

12.2.8.1. Market Revenue and Forecast, by Raw Material (2017-2030)

12.2.9. Germany

12.2.9.1. Market Revenue and Forecast, by Vector (2017-2030)

12.2.9.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.9.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.2.10. Market Revenue and Forecast, by End-User (2017-2030)

12.2.11. Market Revenue and Forecast, by Disease (2017-2030)

12.2.12. France

12.2.12.1. Market Revenue and Forecast, by Vector (2017-2030)

12.2.12.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.12.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.2.12.4. Market Revenue and Forecast, by End-User (2017-2030)

12.2.13. Market Revenue and Forecast, by Disease (2017-2030)

12.2.14. Rest of Europe

12.2.14.1. Market Revenue and Forecast, by Vector (2017-2030)

12.2.14.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.14.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.2.14.4. Market Revenue and Forecast, by End-User (2017-2030)

12.2.15. Market Revenue and Forecast, by Disease (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Vector (2017-2030)

12.3.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.3.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.5. Market Revenue and Forecast, by Disease (2017-2030)

12.3.6. India

12.3.6.1. Market Revenue and Forecast, by Vector (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.3.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.7. Market Revenue and Forecast, by Disease (2017-2030)

12.3.8. China

12.3.8.1. Market Revenue and Forecast, by Vector (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.3.8.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.9. Market Revenue and Forecast, by Disease (2017-2030)

12.3.10. Japan

12.3.10.1. Market Revenue and Forecast, by Vector (2017-2030)

12.3.10.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.10.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.3.10.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.10.5. Market Revenue and Forecast, by Disease (2017-2030)

12.3.11. Rest of APAC

12.3.11.1. Market Revenue and Forecast, by Vector (2017-2030)

12.3.11.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.11.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.3.11.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.11.5. Market Revenue and Forecast, by Disease (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Vector (2017-2030)

12.4.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.4.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.5. Market Revenue and Forecast, by Disease (2017-2030)

12.4.6. GCC

12.4.6.1. Market Revenue and Forecast, by Vector (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.4.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.7. Market Revenue and Forecast, by Disease (2017-2030)

12.4.8. North Africa

12.4.8.1. Market Revenue and Forecast, by Vector (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.4.8.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.9. Market Revenue and Forecast, by Disease (2017-2030)

12.4.10. South Africa

12.4.10.1. Market Revenue and Forecast, by Vector (2017-2030)

12.4.10.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.10.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.4.10.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.10.5. Market Revenue and Forecast, by Disease (2017-2030)

12.4.11. Rest of MEA

12.4.11.1. Market Revenue and Forecast, by Vector (2017-2030)

12.4.11.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.11.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.4.11.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.11.5. Market Revenue and Forecast, by Disease (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Vector (2017-2030)

12.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.5.4. Market Revenue and Forecast, by End-User (2017-2030)

12.5.5. Market Revenue and Forecast, by Disease (2017-2030)

12.5.6. Brazil

12.5.6.1. Market Revenue and Forecast, by Vector (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.5.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.5.7. Market Revenue and Forecast, by Disease (2017-2030)

12.5.8. Rest of LATAM

12.5.8.1. Market Revenue and Forecast, by Vector (2017-2030)

12.5.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.8.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.5.8.4. Market Revenue and Forecast, by End-User (2017-2030)

12.5.8.5. Market Revenue and Forecast, by Disease (2017-2030)

Chapter 13. Company Profiles

13.1. Novasep

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Aldevron

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Merck Waisman Biomanufacturing

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Creative Biogene

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. The Cell and Gene Therapy Catapult

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Cobra Biologics

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. uniQure N.V.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Addgene

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. FUJIFILM Holdings Corporation

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Oxford Biomedicaplc

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

13.11. Takara Bio Inc.

13.11.1. Company Overview

13.11.2. Product Offerings

13.11.3. Financial Performance

13.11.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms